Lung Cancer, Nonsmall Cell Clinical Trial
Official title:
Effect of Qigong on the Symptom Clusters of Dyspnea, Fatigue, and Anxiety.
Effects of Qigong on symptom clusters of dyspnea, fatigue, and anxiety in Vietnamese lung cancer patients: A randomized control trial
Background: Patients with lung cancer experience a variety of symptoms. The number of
symptoms ranged from 7.8 to 13.2, and most of them were at a moderate level of severity.
Dyspnea, fatigue, and anxiety arose as the most problematic symptoms of lung cancer.
Non-pharmacological approaches to manage of symptom among lung cancer patients showed either
no or mild effects. Qigong is hypothesized to alleviate these adverse outcomes; however, all
trial analyzed on a single symptom, and not lung cancer patients, and there have not been
many well-designed randomized control trials. The objectives of this study are following: 1)
to assess the effect of Qigong on managing dypsnea, fatigue, and anxiety (as a cluster) in
lung cancer patients; 2) to explore the effect of Qigong on cough another common symptom
linked with dyspnea, fatigue as a cluster and quality of life (QOL) in lung cancer patients.
Methods: 156 subjects with lung cancer (stage I - IV) will be randomized to either the Qigong
group or the wait-list control group. Participants in the Qigong group will conduct Qigong
practice 5 times per week for 6 weeks, and participants in the control group will receive
usual care. The primary outcome (dypsnea, fatigue, and anxiety), secondary outcomes (cough
and QOL) will be assessed at baseline, post-intervention, and post 6-weeks of follow-up.
Discussion: This study will be the first randomized trial to investigate the effectiveness of
Qigong for management symptom cluster in lung cancer patients. The finding of this study will
help to establish the optimal approach for the care of lung cancer patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06003075 -
Induction Chemo-Nivo in Unresectable Stage III NSCLC
|
Phase 2 | |
| Enrolling by invitation |
NCT06293833 -
Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan
|
N/A | |
| Recruiting |
NCT03705806 -
Palliative Thoracic ImmunoRT
|
||
| Not yet recruiting |
NCT06060964 -
Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management
|
Early Phase 1 | |
| Completed |
NCT04634630 -
The Influence of Cancer Stem-cells on Risk of Relapse in Patients Harboring Adenocarcinoma and Squamous Cell Carcinoma of the Lung
|
||
| Completed |
NCT03689634 -
Move For Surgery - A Novel Preconditioning Program
|
Phase 3 | |
| Recruiting |
NCT05537922 -
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
|
||
| Completed |
NCT03902834 -
Move for Surgery (MFS): Evaluating the Use of Wearable Technology for Preconditioning Before Thoracic Surgery
|
N/A | |
| Active, not recruiting |
NCT03322072 -
Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating
|
N/A | |
| Completed |
NCT02995889 -
FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung Cancer
|
N/A | |
| Recruiting |
NCT04237805 -
A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT05061940 -
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
|
||
| Recruiting |
NCT05860296 -
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
|
Phase 1/Phase 2 | |
| Suspended |
NCT02991651 -
Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC
|
Phase 1 | |
| Enrolling by invitation |
NCT04678440 -
[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients
|
Early Phase 1 | |
| Recruiting |
NCT04222335 -
Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients
|
N/A | |
| Recruiting |
NCT04415320 -
X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
|
Phase 2 | |
| Recruiting |
NCT02786589 -
Plasmodium Immunotherapy for Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05085028 -
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
|
Phase 3 | |
| Completed |
NCT05956782 -
Breathe Easier II: A Dyad-based Multiple Behavior Intervention
|
N/A |